JMT-203

Phase Ia Primary objectives: To evaluate the safety/tolerability of JMT203 in patients with tumor cachexia; To determine the maximum tolerated dose (MTD) (if any) and/or recommended dose for extension (RDE) of JMT203 Secondary objectives: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of JMT203 in patients with tumor cachexia; To evaluate the immunogenicity of JMT203 in patients with tumor cachexia; To evaluate the preliminary efficacy of JMT203 in the treatment of tumor cachexia; Exploratory objectives: To explore the expression of serum GDF15 Correlation between expression level and systemic inflammatory status and cachexia efficacy Phase Ib Main purpose: To evaluate the preliminary efficacy of JMT203 in the treatment of tumor cachexia; To determine the recommended Phase II dose (RP2D) of JMT203 Secondary purpose: To evaluate the improvement of skeletal muscle index in the treatment of tumor cachexia by JMT203; To evaluate the degree of appetite improvement of JMT203 in patients with tumor cachexia; To evaluate the safety of JMT203 in patients with tumor cachexia; To evaluate the PK and PD characteristics of JMT203 in patients with tumor cachexia; To evaluate the immunogenicity of JMT203 in patients with tumor cachexia; To evaluate the survival benefit of JMT203 in patients with tumor cachexia Exploratory purpose: To evaluate the degree of improvement in quality of life and physical function of JMT203 in patients with tumor cachexia; To explore the correlation between serum GDF15 expression level and systemic inflammatory status and cachexia efficacy